NP Scope of Practice + Testosterone Prescribing Law

For the Menopause Telehealth Growth agency. Two questions answered: how nurse practitioners actually operate as menopause clinicians (Colorado and beyond), and whether it's true that "only doctors can prescribe testosterone for women in Colorado" (spoiler: it isn't). Everything sourced; uncertain items flagged.

Question 1: NPs as menopause clinicians

The three-tier map

The AANP classifies every state as Full, Reduced, or Restricted practice for NPs. Full practice authority (FPA) means the NP evaluates, diagnoses, orders tests, and prescribes (including controlled substances) under the Board of Nursing alone, no physician agreement. As of 2026, roughly 29 states plus DC and two territories grant FPA. Live map: AANP State Practice Environment.

Colorado: yes, full practice authority

• Verified. Colorado is an FPA state regulated by the Colorado Board of Nursing. An NP can own and run an independent telehealth menopause practice with zero physician involvement.
• Prescriptive authority is two-stage: newly licensed APRNs get provisional prescriptive authority (already covers Schedule II-V), then must complete a 750-hour prescribing mentorship (mentor can be a physician OR a full-authority APRN) within 3 years to convert to full authority. Rule text: 3 CCR 716-1.15; statute: C.R.S. 12-255-112. This replaced the old, much heavier 1,800-hour + second-mentorship regime (2020-2023 amendments; SB23-167 also folded certified midwives in).
• Colorado requires e-prescribing of Schedule II-IV drugs (SB19-079, in force for APRNs since July 2021).

Prescribing HRT and controlled substances

• Estradiol and progesterone are not controlled substances. In any FPA state an NP prescribes them exactly like an MD. No DEA registration needed for those.
• Testosterone and other controlled substances require the NP's own individual DEA registration (~$888/3 years) plus the one-time federal 8-hour MATE Act training. Colorado adds no separate state controlled-substance license.

Telehealth across state lines: the real constraint

• The clinician must be licensed where the patient sits during the visit, and that state's NP rules apply to that encounter.
• The Nurse Licensure Compact does NOT help: its multistate license covers RN/LPN practice only, not NP-level practice (Nurse.org NLC guide).
• The APRN Compact is not operative as of mid-2026: it needs 7 states, only 5 have enacted it (Delaware, North Dakota, South Dakota, Utah, Wyoming). Colorado hasn't. Activation is plausibly late 2026 or 2027 at the earliest (APRN Compact 2026 status).
• So multi-state NP telehealth means a stack of individual state licenses. That's why platforms match patients to clinicians by state.

How many menopause telehealth clinicians are NPs?

No official statistic exists (flagged: directional, not verified). But Midi Health, the biggest menopause telehealth platform, staffs primarily NPs and nurse midwives, and the mixed MD/NP model is standard across Alloy, Evernow, and Winona (2026 platform comparison). Working assumption: half or more of hands-on menopause telehealth clinicians are NPs, and most solo founders in FPA states are NPs.

NP-run vs MD-run practice

Question 2: "Only doctors can prescribe testosterone for women in Colorado"

Short answer: false as stated

In Colorado, any prescriber with Colorado prescriptive authority plus an individual DEA registration can prescribe testosterone: MD, DO, NP, or PA. There's no Colorado law limiting testosterone (or testosterone for women) to physicians. Real-world proof: telehealth HRT practices operate in Colorado on NP prescribing today (example), and Colorado's own prescriptive authority table shows APNs prescribing Schedules II-V.

What she probably saw instead (all real, all commonly compressed into "only doctors can"):

1. A telehealth company's own state list. Platforms only offer testosterone where THEIR clinicians hold licenses + DEA registrations, and some route testosterone to their physicians as internal policy. Company policy, not Colorado law.
2. The DEA telehealth question (below): risk-averse practices refuse to tele-prescribe testosterone or demand an in-person visit, which patients experience as "my online clinic can't give me testosterone."
3. Compounding friction: no FDA-approved female-dose testosterone product exists, so prescriptions are off-label fractional male doses or compounded creams, and pharmacies vary in what they'll dispense and ship.

The federal backdrop: Schedule III

• Testosterone is a Schedule III anabolic steroid (Anabolic Steroids Control Act, 1990). That means: individual DEA registration to prescribe, maximum 5 refills within 6 months then a new prescription (CSA prescription rules), every fill reported to the state PDMP, and pharmacy-level scrutiny.
• For women it's entirely off-label: no FDA-approved female testosterone product exists in the US. Advocacy to deschedule exists (Sen. Markey letter) but as of July 2026 it remains Schedule III.

The telehealth cliff: Ryan Haight + the DEA flexibilities

• The Ryan Haight Act (2008) normally requires an in-person exam before any controlled substance is prescribed via telemedicine.
• COVID-era waivers suspended that in 2020; DEA has extended them four times. Current status, verified: the Fourth Temporary Extension (DEA press release) runs January 1 through December 31, 2026.
• So today, a telehealth-only menopause NP or MD can legally prescribe testosterone with no in-person exam. That legality expires December 31, 2026 unless DEA extends a fifth time or finalizes the January 2025 proposed Special Registration for Telemedicine rule, which is still not final (analysis, live tracker). This is a genuine regulatory cliff for every tele-testosterone practice.

Colorado specifics

• Nothing stricter than federal on testosterone itself; no physician-only carve-out.
• PDMP: dispensers report all controlled substances daily to the Colorado PDMP; prescribers must register, but the mandatory-query-before-prescribing rule covers opioids and benzodiazepines only, not testosterone.
• E-prescribing required for Schedule II-IV, so testosterone scripts must be electronic.
• Colorado telehealth law is permissive: the patient relationship can be established virtually.

Clinical backdrop (why access friction matters)

Testosterone for women is off-label but guideline-supported for exactly one indication: HSDD in postmenopausal women, per the Global Consensus Position Statement (Davis et al., JCEM 2019, DOI 10.1210/jc.2019-01603), endorsed by The Menopause Society, the Endocrine Society, IMS, ISSWSH and others. Male-only dosing + Schedule III + telehealth uncertainty = real, high-emotion patient friction.

What this means for the agency

1. NPs are fully valid ICP clients. In Colorado and the other ~29 FPA states an NP can own the practice, prescribe everything including testosterone, and be the face of the brand. Don't filter the ICP to MDs.
2. "Why is it so hard to get testosterone" is a validated content pillar. The friction is structural and persists through 2026. Angles: "No, it's not illegal for your NP to prescribe testosterone," "The 5-refill rule explained," "What happens to online testosterone after December 2026."
3. Compliance sensitivities: never imply a client prescribes testosterone "everywhere" (it's per-state-license + DEA registration); keep testosterone claims to the HSDD evidence base; refresh tele-testosterone content when DEA acts on the Dec 31, 2026 expiration.
4. Differentiator: most agencies don't know any of this. Regulatory accuracy baked into client content fits the "every claim sourced" positioning perfectly.

Verified vs uncertain

Verified: Colorado FPA; the provisional + 750-hour mentorship structure; testosterone Schedule III and 5 refills/6 months; DEA flexibilities through Dec 31, 2026; APRN Compact 5 states, not operative; NLC excludes NP practice; Global Consensus 2019 (DOI resolves); CO PDMP query mandate limited to opioids/benzos; CO e-prescribing mandate.

Uncertain / directional: exact NP share of menopause telehealth (no published stat); precise history of Colorado's mentorship-hour reductions (current rule verified); whether DEA finalizes special registration or extends again; which specific article Annette saw (the three-way explanation is inference).

Full working file: testosteroneinwomen/research/regulatory/np-scope-and-testosterone-regulation.md